The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies
Autoimmune diseases group together less than a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (FAI²R: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. In addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. Consequently and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.
Study Type
OBSERVATIONAL
Enrollment
3,000
Blood will be taken in larger quantity.
Purpan University Hospital
Toulouse, France
RECRUITINGConstitution of a collection of biological samples and clinical-biological data from patients with autoimmune diseases
Prospective collection of all available biological samples and clinical data collected during the normal clinical care
Time frame: through study completion, an average of 1 year
Identification and / or validation of new biomarkers for diagnostic and / or prognostic purposes
Use of immune cells and / or biological liquids obtained from patients for cohort studies with new methods of screening (microarray, flow cytometry)
Time frame: through study completion, an average of 1 year
Identification and / or validation of new predictive biomarkers of relapse and / or response to treatment
Use of immune cells and / or biological liquids obtained from patients for cohort studies with new methods of screening (microarray, flow cytometry)
Time frame: through study completion, an average of 1 year
Identification of specificities in these patients in order to improve the diagnosis, treatment decisions and / or the pathophysiological understanding of these diseases
Use of immune cells and / or biological samples for transcriptomic and / or proteomic studies, or in order to be used in experimental animal models
Time frame: through study completion, an average of 1 year
Identification of the determinants of immune reconstitution after cell therapy
Exploring blood cell populations before and after cell therapy with flow cytometry
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.